OakChart

DataMEDS AI Inc

MEDSHealthcare·Medical Distribution·USA·Nano·NASD·Nov 11 • 3:58 PM ET

0.9531+0.0568 (6.34%)
2026-11-12 00:14 CET
Market cap
4.04 USD m
Revenue, TTM
8.02 USD m
Net income, TTM
-88.28 USD m
Free cash flow, TTM
-13.74 USD m
EPS diluted, TTM
-43.30
P/E
-
Compare

Price

MEDS against its 20, 50 and 200-day averages
2050200miss
0.0010.0020.0094.4M188.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MEDSclose 0.9520-day 1.9550-day 2.48200-day 5.120.95

97.3% under the 52-week high of 35.50 on 17 Nov 2025. 52-week low 0.82 on 31 Aug 2026. Last 15 sessions, 216.5% high to low

Volume 0.03× normal · the line is the 50-bar volume average

Profile

MEDS
52-week range, 0% of the way up
0.8235.50

DataMeds AI, Inc. operates as a holding company centered around pharmaceuticals and healthcare services. Its business portfolio consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. The company was founded by Ajjarapu Surendra on September 6, 2022 and is headquartered in Tampa, FL.

IPOFeb 21, 2025
Beta-2.74
ATR, 14d0.36
Rel volume0.03
Short float16.36%
Insider own49.63%
Inst own1.32%

Snapshot

6 groups

Valuation

Index-
Market Cap4.29M
Enterprise Value34.62M
Income-88.28M
Sales8.02M
Book/sh-6.88
Cash/sh0.55
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOFeb 21, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S0.53
P/B-
P/C1.74
P/FCF-
EV/EBITDA-
EV/Sales4.32
Quick Ratio0.10
Current Ratio0.14
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-43.30
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-2054.20% -
Sales past 3/5Y- -
EPS Y/Y TTM-15.07%
Sales Y/Y TTM-78.16%
EPS Q/Q-34.99%
Sales Q/Q-77.15%
EarningsAug 17 BMO
EPS/Sales Surpr.63.64% -

Ownership

Insider Own49.63%
Insider Trans0.00%
Inst Own1.32%
Inst Trans3.24%
ROA-202.97%
ROE-927.67%
ROIC-
Gross Margin-119.55%
Oper. Margin-719.27%
Profit Margin-1100.30%
SMA20-51.00%
SMA50-61.62%
SMA200-81.37%
Trades-

Technical

Shs Outstand2.84M
Shs Float2.27M
Short Float16.36%
Short Ratio0.06
Short Interest0.37M
52W High35.50 -97.32%
52W Low0.82 15.88%
Volatility23.81% 14.02%
ATR (14)0.36
RSI (14)28.78
Beta-2.74
Rel Volume0.03
Avg Volume6.44M
Volume165,437

Performance

Perf Week-36.03%
Perf Month-68.54%
Perf Quarter-36.03%
Perf Half Y-80.35%
Perf YTD-95.23%
Perf Year-96.77%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close0.90
Price0.95
Change %6.34%

Peers

Mkt cap
TickerCompanyMkt cap
YI111 Inc ADR15.21M
MCKMckesson Corp124.67B
CAHCardinal Health Inc64.13B
OMCLOmnicell Inc1.64B
LFMDLifeMD Inc85.80M
HKPDCellyan Biotechnology Co Ltd4.02M
GDRXGoodRx Holdings Inc1.25B
NXPLNextPlat Corp22.50M
GRDNGuardian Pharmacy Services Inc3.17B
PETSPetmed Express Inc23.09M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • DataMEDS AI Announces Corexa Pharmacy's First Commercial Sale of Compounded Peptides Under FDA Enforcement Discretion Policy (ACCESSWIRE) -16.57%
  • DataMeds AI Signs Preliminary Agreement With Florida Health Insurer for GLP-1 Patient Management App (InvestorsHub) -18.12%
  • DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO (ACCESSWIRE)
  • DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent (ACCESSWIRE) -17.22%
  • DataMEDS AI Secures Supply Agreement for Six Compounded Peptides Following FDA Advisory Committee Recommendations (InvestorsHub)
  • DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee (ACCESSWIRE)
  • DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network (ACCESSWIRE)
  • Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License (Business Wire) -15.44%
  • DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies (ACCESSWIRE)
  • DataMeds Regains Compliance With NASDAQ Listing Standards (ACCESSWIRE)
  • DataMeds AI Plans Peptide Compounding Expansion Through Corexa Health Following FDA Policy Proposal (InvestorsHub) -7.72%
  • DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap (ACCESSWIRE)
  • DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform (ACCESSWIRE) -5.94%
  • DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division (InvestorsHub)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-17--0.090-7.132-0.001
2026Q12026-05-18-0.080-0.220-3.2430.060.001
2026Q3---0.080--1.961
2026Q4---0.050--3.101

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-2.700-1.220-49.9840.430.60
2026FY--0.300--5.12
2027FY--0.060--17.22
2028FY-0.170--37.98
2029FY-0.320--52.68
2030FY-0.460--67.63

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-9.8-0.005-2.788-6.6-49.984-43.3038
Period20212022202320242025TTM
EPS, quarterly-0.553-1.797-4.17-26.384-5.284-19.183-13.747-3.243-7.132
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual9.8890018.12923.3388.02
Period20212022202320242025TTM
Sales, quarterly0.0455.67412.4110.8637.7913.0131.6711.561.78
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.5441.0391.0391.0392.0262.836
Period20212022202320242025MRQ
Shares, quarterly1.0391.0391.0391.2291.2631.7892.0262.3882.836
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue8.0223.3418.130.000.00
Cost of Goods Sold Incl. D&A17.6132.9817.480.000.00
Gross Profit-9.59-9.640.650.000.00
Selling, General and Administrative Excl. Other48.1271.566.802.880.01
Other Operating Expense0.000.000.000.000.00
Operating Income-57.71-81.19-6.15-2.88-0.01
Interest Expense5.934.580.830.020.00
Unusual Expense25.2615.540.000.000.00
Net Income Before Taxes-88.28-101.27-6.86-2.90-0.01
Income Taxes0.000.000.000.000.00
Consolidated Net Income-88.28-101.27-6.86-2.90-0.01
Net Income From Continuing Operations-88.28-101.27-6.86-2.90-0.01
Net Income-88.28-101.27-6.86-2.90-0.01
EPS (Recurring)-27.42-44.61-6.60-2.79-0.01
EPS (Basic, Before Extraordinaries)-43.30-49.98-6.60-2.79-0.01
EPS (Diluted)-43.30-49.98-6.60-2.79-0.01
EBITDA-55.39-77.98-5.03-2.88-0.01
Non-Operating Income (Expense)0.630.040.120.000.00
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense27.3754.79---
Price To Sales Ratio0.991.73---
Gross Margin-119.55-41.303.60--
Operating Margin-719.27-347.91-33.90--
Net Margin-1,100.30-433.95-37.82--
Shares Outstanding2.842.031.041.041.04
Market Capitalization4.044.0432.87--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue1.781.561.673.017.7910.8612.415.67
Cost of Goods Sold Incl. D&A1.951.7510.333.588.0910.9711.815.62
Gross Profit-0.17-0.19-8.66-0.57-0.30-0.110.600.05
Selling, General and Administrative Excl. Other7.175.834.1430.985.2031.244.351.80
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.35-6.02-12.80-31.55-5.50-31.35-3.75-1.74
Interest Expense1.562.070.881.431.181.090.690.14
Unusual Expense9.97-0.2514.191.350.000.000.000.00
Net Income Before Taxes-18.36-7.74-27.85-34.32-6.67-32.43-4.33-1.87
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-18.36-7.74-27.85-34.32-6.67-32.43-4.33-1.87
Net Income From Continuing Operations-18.36-7.74-27.85-34.32-6.67-32.43-4.33-1.87
Net Income-18.36-7.74-27.85-34.32-6.67-32.43-4.33-1.87
EPS (Recurring)-4.42-3.31-8.84-18.65-5.28-26.38-4.17-1.80
EPS (Basic, Before Extraordinaries)-7.13-3.24-13.75-19.18-5.28-26.38-4.17-1.80
EPS (Diluted)-7.13-3.24-13.75-19.18-5.28-26.38-4.17-1.80
EBITDA-6.99-5.66-12.00-30.75-4.70-30.55-3.10-1.29
Non-Operating Income (Expense)0.510.100.010.010.010.010.100.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.100.200.3625.720.9427.77--
Price To Sales Ratio0.990.821.732.331.669.16--
Gross Margin-9.80-11.97-518.27-18.98-3.81-1.014.850.95
Operating Margin-412.68-385.72-766.04-1,047.11-70.60-288.57-30.20-30.75
Net Margin-1,031.72-496.46-1,667.19-1,139.04-85.64-298.53-34.90-32.91
Shares Outstanding2.842.392.031.791.261.231.041.04
Market Capitalization4.0411.5140.4779.3561.16265.51198.43-

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments0.041.030.000.00
Short Term Receivables1.143.750.340.00
Inventories1.649.520.000.00
Other Current Assets0.000.000.000.00
Total Current Assets2.8214.290.340.00
Net Property, Plant & Equipment1.201.920.000.00
Total Investments and Advances0.000.020.000.00
Long-Term Note Receivable0.000.14--
Intangible Assets26.3638.580.000.00
Deferred Tax Assets0.00---
Other Assets0.092.380.000.00
Total Assets30.4657.330.340.00
Short Term Debt Incl. Current Port. of LT Debt11.6412.560.350.00
Accounts Payable11.696.330.000.00
Other Current Liabilities6.4519.152.890.01
Total Current Liabilities29.7838.053.240.01
Long Term Debt13.1312.550.000.00
Provision for Risks Charges0.000.000.000.00
Deferred Tax Liabilities0.00---
Other Liabilities0.000.000.000.00
Total Liabilities42.9150.603.240.01
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00
Common Equity-12.456.73-2.90-0.01
Total Shareholders Equity-12.456.73-2.90-0.01
Accumulated Minority Interest0.000.000.000.00
Total Equity-12.456.73-2.90-0.01
Total Liabilities & Stockholders Equity30.4657.330.340.00
Book Value Per Share-6.146.48-2.79-0.01
Tangible Book Value Per Share-19.15-30.66-2.79-0.01
Price to Book Ratio-0.134.85--
Return on Assets-230.71-23.78-1,711.58-
Return on Equity--357.65--
Return on Invested Capital-14,908.20-35.55--
Quick Ratio0.040.130.100.00
Current Ratio0.090.380.100.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-88.28-101.27-6.86-2.90-0.01
Depreciation2.323.211.11--
Other Funds (Non Cash)64.6878.721.170.000.00
Funds from Operations-21.28-19.34-4.57-2.90-0.01
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital7.548.483.342.550.01
Cash from Operating Activities-13.74-10.86-1.22-0.350.00
Capital Expenditures-0.92-0.88-0.460.000.00
Net Assets From Acquisitions0.000.000.930.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.00
Purchase of Investments0.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-0.92-0.880.470.000.00
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock8.3412.86-0.150.000.00
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock8.3412.86-0.150.000.00
Proceedsfrom Stock Options6.0510.56-0.150.000.00
Issuance or Reduction of Debt, Net8.35-2.110.620.350.00
Change in Long Term Debt8.35-2.110.000.000.00
Issuance of Long Term Debt19.6524.150.000.000.00
Reduction of Long Term Debt-11.30-26.260.000.000.00
Net Financing Active Other Cash Flow0.000.001.310.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities16.7010.751.780.350.00
Net Change in Cash2.04-0.991.030.00-
Free Cash Flow-13.74-10.86-1.31-0.350.00
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments2.460.050.044.230.422.52
Short Term Receivables1.201.001.141.103.993.97
Inventories1.511.711.647.499.039.73
Other Current Assets0.47-0.000.000.070.34
Total Current Assets5.632.762.8212.8213.5116.55
Net Property, Plant & Equipment0.891.051.201.291.591.75
Total Investments and Advances0.000.000.000.000.000.02
Intangible Assets26.1526.2426.3636.9237.4638.09
Deferred Tax Assets--0.00---
Other Assets0.090.090.091.611.521.51
Total Assets32.7630.1330.4652.7854.2358.06
Short Term Debt Incl. Current Port. of LT Debt19.9415.9211.6412.9413.9518.38
Accounts Payable12.6412.0011.6910.449.488.21
Other Current Liabilities6.844.276.459.3718.9819.63
Total Current Liabilities39.4132.2029.7832.7442.4046.23
Long Term Debt12.8512.9913.1313.2610.927.36
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.00---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities52.2645.1942.9146.0053.3253.58
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-19.50-15.06-12.456.780.914.48
Total Shareholders Equity-19.50-15.06-12.456.780.914.48
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-19.50-15.06-12.456.780.914.48
Total Liabilities & Stockholders Equity32.7630.1330.4652.7854.2358.06
Book Value Per Share-6.88-6.31-6.143.790.723.64
Tangible Book Value Per Share-16.09-17.29-19.15-16.85-28.95-27.35
Price to Book Ratio-0.13-0.76-3.2511.7167.5659.28
Return on Assets-202.97-173.68-230.71-143.52-155.15-132.98
Return on Equity----927.67--5,209.10
Return on Invested Capital---4,100.12-171.26-56.44-273.96
Quick Ratio0.100.030.040.160.110.15
Current Ratio0.140.090.090.390.320.36

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-18.36-7.74-27.85-34.32-6.67-32.43
Depreciation0.360.360.800.800.800.80
Other Funds (Non Cash)12.222.6822.2327.561.0727.87
Funds from Operations-5.78-4.71-4.82-5.96-4.80-3.76
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.891.30-1.474.822.722.41
Cash from Operating Activities-2.89-3.41-6.29-1.14-2.08-1.35
Capital Expenditures-0.24-0.21-0.26-0.22-0.13-0.27
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.24-0.21-0.26-0.22-0.13-0.27
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-1.160.002.966.540.962.40
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-1.160.002.966.540.962.40
Proceedsfrom Stock Options-1.160.000.666.540.962.40
Issuance or Reduction of Debt, Net6.703.63-0.60-1.38-0.680.24
Change in Long Term Debt6.703.63-0.60-1.38-0.140.00
Issuance of Long Term Debt8.206.002.902.5518.700.00
Reduction of Long Term Debt-1.50-2.38-3.50-3.93-18.830.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.470.47
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities5.543.632.365.170.113.11
Net Change in Cash2.400.01-4.193.81-2.101.49
Free Cash Flow-2.89-3.41-6.29-1.14-2.08-1.35

Revenue breakdown

Pharmacy Retail Sales2024: 352.36K 2025: 865.70K
Product2024: 17.67M 2025: 21.87M
Third Party Logistics Services2024: 107.00K 2025: 603.42K
United States2024: 18.13M 2025: 23.34M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.36%0.4M2.3M6.42M
2026-10-1520.98%0.5M2.3M6.31M
2026-09-3034.10%0.5M1.5M5.23M
2026-09-1527.96%0.4M1.5M1.30M
2026-08-3113.59%0.2M1.3M262.32K
2026-08-1413.51%0.2M1.2M524.40K
2026-07-319.72%0.1M1.1M556.36K
2026-06-3010.85%0.1M1.0M734.95K
2026-06-1516.08%0.1M0.6M731.78K
2026-05-2970.57%0.4M0.6M756.96K
2026-05-150.33%0.2M62.3M313.95K
2026-04-305.39%0.1M1.0M248.87K
2026-04-1531.48%0.3M1.0M239.88K
2026-03-316.16%0.1M0.9M52.91K
2026-03-1315.90%0.1M0.8M39.88K
2026-02-274.98%0.0M0.8M14.56K
2026-02-133.37%0.0M0.8M11.96K
2026-01-302.02%0.0M0.8M15.79K
2026-01-151.63%0.0M0.8M280.29K
2025-12-311.76%0.0M0.8M278.51K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10S-1/ASEC
2026-11-10SCHEDULE 13GSEC
2026-11-09DEF 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-11-09SEC
2026-11-058-KCurrent report2026-11-03SEC
2026-10-268-KCurrent report2026-10-21SEC
2026-10-208-KCurrent report2026-10-19SEC
2026-10-168-KCurrent report2026-10-13SEC
2026-10-138-KCurrent report2026-10-13SEC
2026-10-09PRE 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-10-09SEC
2026-10-09S-1/ASEC
2026-09-178-KCurrent report2026-09-11SEC
2026-09-168-KCurrent report2026-09-11SEC
2026-08-31PRE 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-08-31SEC
2026-08-188-KCurrent report2026-08-17SEC
2026-08-1710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-14NT 10-Q2026-06-30SEC
2026-08-07S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-048-KCurrent report2026-07-29SEC
2026-07-298-KCurrent report2026-07-27SEC
2026-07-218-KCurrent report2026-07-20SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-254/A2026-03-31SEC
2026-06-254/A2026-03-31SEC
2026-06-18PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-18SEC
2026-06-128-KCurrent report2026-06-09SEC
2026-06-11DRS/ASEC
2026-06-038-K/A2026-05-27SEC
2026-06-028-K/A2026-05-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JANE STREET GROUP, LLC0.78%
OneDigital Investment Advisors LLC0.67%
GEODE CAPITAL MANAGEMENT, LLC0.60%
VANGUARD CAPITAL MANAGEMENT LLC0.42%
UBS Group AG0.31%
VANGUARD FIDUCIARY TRUST CO0.24%
CITIGROUP INC0.06%
Tower Research Capital LLC0.03%
BARCLAYS PLC0.00%
Fortitude Family Office, LLC0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.38%
VANGUARD EXTENDED MARKET INDEX FUND0.34%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.08%
Fidelity Series Total Market Index Fund0.05%
Fidelity Nasdaq Composite Index Fund0.04%
Fidelity Total Market Index Fund0.03%

OakChart. MEDS. Cached 15 minutes.

Some panels did not load: ratings, insider.